A retrospective cohort study on predictors of renal function decline in a population at risk for the onset and progression of chronic kidney disease

A retrospective cohort study on predictors of renal function decline in a population at risk for the onset and progression of chronic kidney disease - A retrospective cohort study on predictors of renal function decline in a population at risk for the onset and progression of chronic kidney disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060879

Enrollment

1500

Registered

2026-03-09

Start date

2026-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who visited the Department of Nephrology, Hypertension, and Endocrinology at Nihon University Itabashi Hospital and were diagnosed with chronic kidney disease, or those with diabetes, hypertension, or obesity who were considered to be at high risk of developing chronic kidney disease in the future, from January 1, 2014 to February 1, 2030.

Exclusion criteria

Exclusion criteria: 1. Persons who express their unwillingness to participate in this study. 2. Persons deemed by the principal investigator to be unsuitable for inclusion in this study for any reason.

Design outcomes

Primary

Measure	Time frame
Renal function decline will be evaluated based on the estimated glomerular filtration rate (eGFR) at baseline and the subsequent eGFR slope (annual rate of decline in eGFR). Associations between renal function decline and patient background characteristics, comorbidities, blood pressure, laboratory data, concomitant medications, and existing clinical items, including nutritional counseling, will be examined.	—

Measure

Time frame

Renal function decline will be evaluated based on the estimated glomerular filtration rate (eGFR) at baseline and the subsequent eGFR slope (annual rate of decline in eGFR). Associations between renal function decline and patient background characteristics, comorbidities, blood pressure, laboratory data, concomitant medications, and existing clinical items, including nutritional counseling, will be examined.

—

Secondary

Measure	Time frame
Renal function decline (CKD progression):eGFR at baseline; subsequent eGFR slope (annual rate of decline in eGFR); associations with patient background characteristics, comorbidities, blood pressure, laboratory data, concomitant medications, and existing clinical items, including nutritional counseling Use of renoprotective medications: including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, antihypertensive medications; prescription rates, initiation, continuation, discontinuation, and combination patterns Cardiovascular events and all-cause mortality Annual clinical laboratory data: eGFR, Cr, liver function tests, HbA1c, blood pressure, lipid profile, CRP, Na, K, markers of kidney injury, urinary protein Imaging examinations: ABI, echocardiography, chest X-ray Treating physician information Concomitant medications based on medical records: Use of SGLT2 inhibitors, RAS inhibitors, finerenone, GLP-1 receptor agonists, ACE inhibitors/ARBs, and diuretics, and their impact on renal function decline Associations between renal function decline and multidisciplinary collaboration, including nutritional counseling and chronic kidney disease self-management education Comorbidity information: Diabetes mellitus, cardiovascular disease, hypertension, and other comorbidities Prognostic information: ESKD, cardiovascular events, mortality Baseline information at the time of informed consent: Sex, age, medical history, smoking history, body size, and other relevant baseline characteristics	—

Measure

Time frame

Renal function decline (CKD progression):eGFR at baseline; subsequent eGFR slope (annual rate of decline in eGFR); associations with patient background characteristics, comorbidities, blood pressure, laboratory data, concomitant medications, and existing clinical items, including nutritional counseling Use of renoprotective medications: including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, antihypertensive medications; prescription rates, initiation, continuation, discontinuation, and combination patterns Cardiovascular events and all-cause mortality Annual clinical laboratory data: eGFR, Cr, liver function tests, HbA1c, blood pressure, lipid profile, CRP, Na, K, markers of kidney injury, urinary protein Imaging examinations: ABI, echocardiography, chest X-ray Treating physician information Concomitant medications based on medical records: Use of SGLT2 inhibitors, RAS inhibitors, finerenone, GLP-1 receptor agonists, ACE inhibitors/ARBs, and diuretics, and their impact on renal function decline Associations between renal function decline and multidisciplinary collaboration, including nutritional counseling and chronic kidney disease self-management education Comorbidity information: Diabetes mellitus, cardiovascular disease, hypertension, and other comorbidities Prognostic information: ESKD, cardiovascular events, mortality Baseline information at the time of informed consent: Sex, age, medical history, smoking history, body size, and other relevant baseline characteristics

—

Countries

Japan

Contacts

Public ContactHiroki Kobayashi

Nihon University School of Medicine Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine

kobayashi.hiroki@nihon-u.ac.jp+81-3-3972-8111

Outcome results